


Biocon rides on emerging markets


11 June 2010 | News

image not found or type unknown



1


image not found or type unknown



Head:
Kiran Mazumdar-Shaw

Business:
Biopharmaceuticals

image not found or type unknown



Startup Year:

1978

Address:

20th KM Hosur Road, Electronic
City, Bangalore -560100,
Karnataka

Tel:

+91-80-28082808

Fax:

+91-80-28523423

Website:

www.biocon.com

With a total revenue of Rs 1,180 crore in FY 2009-10, Biocon is back to the number one position in the BioSpectrum-ABLE Top 20 Survey 2010. after a gap of three years. Including its German subsidiary, Axicorp, the PAT of the company stood at Rs 293 crore with a year-on-year growth of 215 percent. The company also increased its licensing revenue.

Biocon's insulin business grew by 11 percent. In FY 2009-10, Biocon entered several new markets like Brazil and Chile. It also secured registration approvals in five countries during this year. The statin business of the company registered a year-on-year growth of 26 percent despite pricing pressures owing to enhanced capacity enabled by improved productivity. Simvastatin remained as the largest revenue incurring product by sales but expected to boost the revenue in the coming years.

Axicorp posted 93 percent growth. The growth primarily came from more efficient sourcing of products for its business, restructuring of its sales force, and winning AOK, generics.

Biocon has acquired a new API facility in Hyderabad and is expanding its monoclonal antibody facility of its subsidiary, Biocon Biopharmaceuticals, which has recently been wholly-acquired from its Cuban partner. Its oncology segment posted 59 percent growth with brands like Abraxane and BioMAb EGFR as key contributors. The company plans to expand its auto-immune portfolio into dermatology and rheumatoid arthritis by launching r.

Kiran Mazumdar-Shaw, CMD of Biocon, said, "We are confident of sustaining growth momentum in the years ahead given our increasingly differentiated profile enhanced by key global partnerships. This offers us larger and lucrative opportunities in both emerging

Considering R&D pipeline, the company has strengthened its partnership with Mylan for developing biosimilars for the global markets. Its novel pipeline has achieved significant milestones spearheaded by a key IND filing with the US FDA for its oral insulin program

Biocon's coveted T1h program, a novel anti-cd6 targeting monoclonal antibody, is also entering phase-III clinical trials for psoriasis. Additionally, its novel anti-CD20 molecule has completed preclinical studies and is expected to move into the clinical trial in India

Among other developments, Biocon has signed a MoU with Malaysian Biotechnology Corporation to explore collaboration and potential investment in Malaysia's biotech industry. Biocon is in talks with Biotech Corp to manufacture biopharma products and

Having a strong focus on R&D, the company in FY 2009-10, spent Rs 125 crore in research, a 45 percent rise over the previous year's investment of Rs 80 crore.